iBio announces licensing agreement with AstralBio

Bio announced a licensing agreement with AstralBio for a preclinical first-in-class antibody targeting Activin E, which was discovered using iBio‘s (IBIO) patented Machine-Learning Antibody Engine. Activin E is a promising novel therapeutic target whose inhibition is believed to induce fat-selective weight loss and offer protection against obesity and cardiometabolic disease. iBio plans to rapidly advance testing of the antibody in more complex models following preclinical studies that demonstrated strong antibody binding, inhibition of Activin E signaling and fat-specific weight loss in an obese rodent animal model.